Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Preliminary revenue and cash estimates for three and nine months ended September 30, 2026.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary revenue and cash estimates for three and nine months ended September 30, 2026
- Preliminary cash includes estimated one-time severance and retention payments during Q3 2026
- Actual financial results remain unfinalized, creating potential revision risk for investors
- New and updated ZYNLONTA clinical data planned across five oral presentations at ASH, December 12–15, 2026
Item 7.01 · Regulation FD Disclosure
- New and updated ZYNLONTA trial data scheduled across multiple ASH abstracts, including five oral presentations, December 12–15, 2026
- Investor focus: clinical updates could influence ZYNLONTA’s commercial outlook and ADC Therapeutics’ valuation
- Presentation includes preliminary revenue for three and nine months ended September 30, 2026
- Preliminary September 30 cash balance includes estimated one-time severance and retention payments during the quarter
- Preliminary figures remain subject to material revision before subsequent SEC filings
Item 8.01 · Other Events
- LOTIS-7 ZYNLONTA plus glofitamab: 88.7% ORR and 75.3% CRR in 97 evaluable large B-cell lymphoma patients
- Durability remains encouraging: 79.0% 12-month complete-response rate, with median response duration and PFS not reached
- Activity persisted in difficult populations: 78.4% ORR in primary refractory disease and 74.1% after prior CAR-T therapy
- Safety remains material: three Grade 5 events, including two capillary leak syndrome deaths, alongside 36.9% Grade ≥3 neutropenia
- Marginal zone lymphoma study showed 93% ORR, 74.4% CRR and 90.8% two-year PFS, supporting ZYNLONTA expansion potential beyond current indications
Item EX-99.1 · Exhibit EX-99.1
- ASH data broaden ZYNLONTA’s commercial opportunity beyond current late-line DLBCL approval, including MZL and combination therapy with glofitamab
- LOTIS-7: ORR 88.7%, CRR 75.3% among 97 patients, with 12-month complete-response duration rate 79.0%
- LOTIS-7 supports planned Phase 3 development, but CRS occurred in 32% and three Grade 5 treatment-emergent events were reported
- MZL Phase 2: ORR 93%, CRR 74.4%, two-year PFS 90.8%, and 24-month response-duration rate 90.9%
- LOTIS-5: PFS improved to 6.14 versus 4.73 months versus R-GemOx, but overall survival was not statistically different and Grade 5 events varied by reporting window
Item EX-99.2 · Exhibit EX-99.2
- ASH update supports ZYNLONTA expansion, with LOTIS-7 ORR 88.7% and CR 75.3% in 97 evaluable patients
- LOTIS-5 met its PFS endpoint, HR 0.73 and p=0.008, but Grade 5 adverse events were higher, 13.2% versus 4.6%
- MZL study showed ORR 93% and CR 74.4%, supporting planned Breakthrough Therapy Designation submission in H1 2027
- $86.6M private placement and debt refinancing extend expected cash runway into 2029, with senior loan principal reduced to $50M
- Preliminary Q3 2026 ZYNLONTA revenue expected at $21M, while cash was $189.2M at September 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.